{
  "reviewed": "2026-09-20",
  "scope": "Major clinical and longevity claims; not every financial or biographical detail",
  "claim_count": 13,
  "claims": [
    {
      "id": "five-year-forecast",
      "claim": "Five more years guarantees access to radical life extension",
      "status": "Not established",
      "finding": "The reviewed evidence does not support a five-year clinical rescue deadline or demonstrated whole-body human age reversal.",
      "sources": [
        "https://www.youtube.com/watch?v=dQYKcjvXhIY"
      ]
    },
    {
      "id": "mouse-osk",
      "claim": "Three genes restored vision",
      "status": "Peer-reviewed mouse evidence",
      "finding": "Lu et al. studied OSK expression in mouse retinal ganglion cells, axon regeneration and visual-function outcomes; not human or whole-body rejuvenation.",
      "sources": [
        "https://www.nature.com/articles/s41586-020-2975-4",
        "https://pubmed.ncbi.nlm.nih.gov/36599349/"
      ]
    },
    {
      "id": "er100-human",
      "claim": "Partial reprogramming works in humans",
      "status": "First dosing announced; efficacy not established",
      "finding": "Sponsor announced first participant dosed June 9, 2026, not an exact administration date. NCT07290244 is Phase 1, open-label, non-randomized; estimated enrollment 18. Last posted update May 19, 2026 lists recruiting and no results posted. Safety/tolerability focus, not lifespan.",
      "sources": [
        "https://www.lifebiosciences.com/life-biosciences-announces-first-patient-dosed-in-phase-1-trial-of-er-100-for-optic-neuropathies/",
        "https://clinicaltrials.gov/study/NCT07290244"
      ]
    },
    {
      "id": "ai-tools",
      "claim": "AlphaFold, protein design and Evo solve biology",
      "status": "Real technical advances; clinical extrapolation unsupported",
      "finding": "Structure prediction and laboratory protein/editor validation do not establish safety or therapeutic efficacy. EvoCas9-1 showed laboratory DNA cleavage, not an approved human therapy.",
      "sources": [
        "https://www.nature.com/articles/s41586-021-03819-2",
        "https://www.nature.com/articles/s41586-023-06415-8",
        "https://www.science.org/doi/10.1126/science.ado9336"
      ]
    },
    {
      "id": "retro-50x",
      "claim": "AI makes reprogramming 50 times better",
      "status": "Company-reported in-vitro marker result",
      "finding": "OpenAI's August 22, 2025 report describes greater than 50-fold higher stem-cell reprogramming marker expression versus wild-type controls, plus other laboratory characterization. Not 50-fold rejuvenation, vision benefit or lifespan. Internal replication differs from independent clinical validation.",
      "sources": [
        "https://openai.com/index/accelerating-life-sciences-research-with-retro-biosciences/"
      ]
    },
    {
      "id": "rentosertib",
      "claim": "AI-designed drug improved lung function",
      "status": "Randomized phase 2a signal",
      "finding": "71 randomized, 12 weeks, primary safety endpoint; secondary FVC signal +98.4 mL in highest once-daily group versus -20.3 mL placebo. 55 completed treatment; liver toxicity and other adverse events matter. No lifespan-extension endpoint demonstrated.",
      "sources": [
        "https://www.nature.com/articles/s41591-025-03743-2",
        "https://www.nature.com/articles/s41591-025-03743-2.pdf"
      ]
    },
    {
      "id": "casgevy",
      "claim": "CRISPR has become prescribed medicine",
      "status": "Verified specific U.S. approval",
      "finding": "FDA December 2023 Casgevy approval is disease-specific, with severe-crisis freedom endpoint and chemotherapy/transplant burden. It is not general anti-aging approval or a claim of Canadian access.",
      "sources": [
        "https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease"
      ]
    },
    {
      "id": "xenotransplant",
      "claim": "Pig organs demonstrate human aging reversal",
      "status": "Human organ-support evidence; not aging reversal",
      "finding": "Towana Looney's 130-day graft and later dialysis are confirmed by NYU. Newer Andrews case reports 271 dialysis-free days, subsequent graft failure and later human kidney transplant. Individual cases and EXPAND trial entry do not establish general survival benefit or routine approval.",
      "sources": [
        "https://nyulangone.org/news/pig-kidney-recipient-returns-home-after-transplant-breakthrough-nyu-langone-health",
        "https://news.massgeneralbrigham.org/en/pig-kidney-xenotransplant-bridge-to-human-transplant",
        "https://doi.org/10.1016/S0140-6736(26)01295-X",
        "https://nyulangone.org/news/first-gene-edited-pig-kidney-transplant-clinical-trial-begins-nyu-langone-health"
      ]
    },
    {
      "id": "senolytic-failure",
      "claim": "UNITY knee trial failed",
      "status": "Verified, but video citation mismatch",
      "finding": "UBX0101 phase 2 randomized 183 patients and did not meet week-12 WOMAC-A pain endpoint. Description instead links PMID31542391, a different nine-person dasatinib/quercetin diabetic-kidney study.",
      "sources": [
        "https://www.globenewswire.com/news-release/2020/08/17/2079116/0/en/unity-biotechnology-announces-12-week-data-from-ubx0101-phase-2-clinical-study-in-patients-with-painful-osteoarthritis-of-the-knee.html",
        "https://pubmed.ncbi.nlm.nih.gov/31542391/"
      ]
    },
    {
      "id": "masai",
      "claim": "AI screening finds more cancer and reduces interval cancers",
      "status": "Detection gain supported; interval-cancer superiority not established",
      "finding": "2025: 6.4 versus 5.0 detected cancers/1000. 2026: interval cancer 1.55 versus 1.76/1000, ratio 0.88 (95% CI 0.65–1.18), non-inferiority but no significant overall reduction. Mortality benefit not demonstrated by these endpoints. Cited 2023 paper alone does not contain later results.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/37541274/",
        "https://pubmed.ncbi.nlm.nih.gov/39904652/",
        "https://pubmed.ncbi.nlm.nih.gov/41620232/"
      ]
    },
    {
      "id": "mayo-ecg",
      "claim": "The cited AI ECG study predicts rhythm disease years ahead and saves lives",
      "status": "Overextends cited study",
      "finding": "2019 retrospective AF classification during sinus rhythm, including 31-day pre-recorded-AF window; no randomized mortality/stroke benefit or general years-ahead prediction established in that paper.",
      "sources": [
        "https://pubmed.ncbi.nlm.nih.gov/31378392/"
      ]
    },
    {
      "id": "isomorphic-timeline",
      "claim": "Isomorphic's first AI cancer drug cleared January 2026",
      "status": "Specific claim not corroborated",
      "finding": "Reuters January20 reported first trials targeted by end2026. Insilico January23 announced ISM8969 IND for Parkinson's, a different company and indication. Video names no drug, so intended source cannot be confirmed; no approval inferred.",
      "sources": [
        "https://www.reuters.com/business/healthcare-pharmaceuticals/google-backed-ai-drug-discovery-startup-isomorphic-labs-delays-clinical-trial-2026-01-20/",
        "https://insilico.com/news/az7xmeem81-insilico-medicine-receives-ind-approval?amp=true"
      ]
    },
    {
      "id": "longevity-limits-supplements",
      "claim": "Biomarker improvement and longevity forecasts prove lifespan extension",
      "status": "Not established",
      "finding": "NAD clinical review finds limited efficacy. Lifespan-limit statistical interpretation remains contested. Biological-age scores, disease outcomes and measured survival are different endpoints.",
      "sources": [
        "https://www.nature.com/articles/s42255-025-01387-7",
        "https://www.nature.com/articles/nature19793",
        "https://pmc.ncbi.nlm.nih.gov/articles/PMC5654601/"
      ]
    }
  ]
}